As you might expect, sellers look for a premium multiple. Buyers typically will only consider paying a premium to market if they are adequately convinced that the value of the potential target justifies it. This begs the question: How does one derive a rationale for discount and premium multiples on a business? There are a […]

Read More

Are you unusually busy? If you’re like most people the answer is yes! With the holiday season upon us, we are most of us inundated with commitments to work, family and friends. While it might be easy to get caught up in the bustle of the season, I recommend pausing to plan your growth path […]

Read More

Deferring to advisors during the M&A process can be detrimental to a company, as evidenced by the back and forth over Valeant Pharmaceuticals’ unsolicited $53 billion bid to acquire Allergan, the maker of Botox. The maneuvering over the past several months has become heated and off-track. Or as the Deal Professor column puts it: “Some […]

Read More

While G.E. may have Alstom’s support to acquire its energy business, the company has yet to gain the support of the French government. On Wednesday, G.E. chief executive Jeffery Immelt will visit French President François Holland for the second time to discuss G.E.’s $13.5 billion bid for Alstom’s energy business. If G.E. and the French […]

Read More